SLS

Sellas Life Sciences Group Stock Analysis

AI Rating

Good
  • Quality2/10
  • Growth 7/10
  • Momentum 9/10
Sellas Life Sciences Group sales and earnings growth
SLS Growth
Good
  • Revenue Y/Y 0.00%
  • EPS Y/Y 59.42%
  • FCF Y/Y 7.42%
Sellas Life Sciences Group gross and profit margin trends
SLS Profitability
Low
  • Gross margin 0.00%
  • EPS margin 0.00%
  • ROIC 1520.90%
Sellas Life Sciences Group net debt vs free cash flow
SLS Risk
Great
  • Debt / Equity 0.0
  • Debt / FCF 0.0
  • Interest coverage NA

Sellas Life Sciences Group stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗